CJC-1295 w/o DAC

This is a laboratory copy of the first 29 amino acids of growth hormone-releasing hormone (GHRH), the message your brain sends to the pituitary gland telling it to release growth hormone, with a handful of amino acids swapped out so that blood enzymes cannot chew it up as fast. The name is a piece of market shorthand rather than chemistry. The compound actually called CJC-1295 in the published literature carries an extra chemical hook, the drug affinity complex (DAC), that clamps it onto albumin in your blood so it keeps working for roughly a week. Strip that hook off and you are left with the peptide sold here, which the scientific literature calls modified growth hormone-releasing factor, written GRF (1-29), or tetrasubstituted GRF(1-29), and which clears in a matter of hours instead. It is not growth hormone, and it does not contain any. It is a request sent to your own pituitary, so it only does anything if that gland still works.

• Raising your own growth hormone and insulin-like growth factor 1 (IGF-1) without injecting growth hormone itself
• Timing a single growth hormone pulse to land at a chosen moment, usually the start of deep sleep
• Body composition goals — less fat, more lean mass — over months rather than weeks
• Recovery from hard training and general wear and tear
• Pairing with a ghrelin-mimetic such as ipamorelin, on the theory that hitting two receptors beats hitting one
• Age-related decline in growth hormone output, which is a clinic-marketing use rather than an approved one

Picture your pituitary as a water tower with a release valve that opens in bursts through the night. Native GHRH is a hand that squeezes that valve, but it is snipped in half by an enzyme in your blood within a couple of minutes. This peptide is the same hand wearing a glove that the enzyme cannot cut, so the squeeze lasts long enough to matter. Attach the DAC hook and the hand gets tied to the lever for a week; leave it off, as here, and the hand lets go after an hour or two, which is the whole point of the DAC-free version.

1. First 2 hoursThis is the only window with a measured shape. In the nearest human trial of a modified GRF(1-29) analogue, a nightly injection produced a growth hormone release that began within 10 minutes and lasted about two hours (Khorram et al., 1997). Nothing has been published on the exact peptide sold as CJC-1295 without DAC.
2. Week 1-2Blood chemistry moves before anything else does. In that same trial, IGF-1 and its binding protein IGFBP-3 were already elevated within two weeks of nightly dosing.
3. Week 4-8If anything visible happens, this is the earliest it would show. No published study has tracked body composition on this peptide, so there is no number to quote here.
4. Month 3+Over 16 weeks of nightly dosing with a related GHRH(1-29) analogue, skin thickness rose in both sexes and lean body mass rose in men only, with no lean-mass change in women (Khorram et al., 1997). That was a different molecule, so treat it as the nearest map rather than the territory.
5. Post-cycleThe DAC-free peptide clears within hours rather than days, so the drive on the pituitary stops quickly after the last injection. Whether IGF-1 settles back to where it started has not been tracked for this compound.

• Injection site reactions — redness, itching, a small welt — reported as the main complaint in the CJC-1295 human dose-ranging work.
• Flushing and a brief warm feeling shortly after dosing, which is the classic GHRH reaction.
• Transient hyperlipidaemia, the only adverse effect recorded in the 16-week nightly trial of a related GHRH(1-29) analogue, and it resolved by the end of the study (Khorram et al., 1997).
• The FDA's compounding record for CJC-1295 states that the agency identified serious adverse events including increased heart rate and a systemic vasodilatory reaction.
• Water retention, puffy hands or feet, and joint or wrist aching. These come with pushing growth hormone and IGF-1 up and are described in the 2026 review of GH-axis performance peptides as fluid retention syndromes and myalgia or arthralgia.
• Dysglycaemia — drifting fasting glucose and reduced insulin sensitivity — is listed among the reported effects of this class in that same review. Note that the 16-week analogue trial found the opposite in men, where insulin sensitivity improved, so the direction is not settled.
• Because this peptide is sold as a research chemical rather than a medicine, impurity and sterility problems are a live risk on top of the pharmacology. The FDA's record flags peptide-related impurities and immunogenicity for certain routes of administration.

• You are pregnant, trying to conceive, or breastfeeding. There is no human safety data for this peptide in pregnancy, and none for the DAC version either.
• You have an active cancer or a personal history of one. Growth hormone and IGF-1 are growth signals, and deliberately raising them in that setting is not something the literature supports.
• You have diabetes, prediabetes, or diabetic retinopathy, because sustained growth hormone elevation can work against insulin sensitivity.
• You have an untreated pituitary lesion, or a diagnosis of acromegaly.
• You are a child or adolescent with open growth plates, unless an endocrinologist is directing it.
• You are an athlete subject to drug testing. GHRH analogues are prohibited at all times under section S2 of the World Anti-Doping Agency Prohibited List, and assays that detect them in urine and plasma are already published and validated.
• You are not working with a physician who can order IGF-1, fasting glucose and HbA1c before and during use.

• Assuming it is the same molecule as the CJC-1295 in the published trials. It is not. Every half-life figure, every growth hormone fold-change and every safety statement in that literature comes from the DAC version, which lasts about a week; this one lasts hours.
• Dosing after a meal. Carbohydrate and the insulin response to it blunt the growth hormone pulse, which is why the cheatsheet timing is before sleep rather than after dinner.
• Dosing once a day and expecting the DAC version's continuous elevation. A peptide with a short half-life gives you one pulse per injection, and once-daily was specifically the schedule that worked for the long-acting form in animal work.
• Reconstituting badly. Use bacteriostatic water, aim the stream at the glass wall rather than straight at the powder, and swirl instead of shaking. Peptides in solution are fragile.
• Storing the mixed vial in the fridge door, where the temperature swings every time it opens, or leaving it at room temperature between doses.
• Stacking a second growth hormone secretagogue on the assumption that more receptors means more benefit, without checking fasting glucose. The metabolic cost of that combination has not been characterised for this peptide.